Our Services
Pre-clinical services – In vitro
The PANGAEA LAB team is composed of prestigious research professionals and combines expertise in preclinical cancer research with extensive experience in R&D diagnostics.
In-house and through partnerships we perform comprehensive pathology, molecular biology, in vitro and in vivo techniques:
- Next Generation Sequencing (NGS)
- Multiplex hybridization (NanoString nCounter technology)
- Quantitative PCR (qPCR)
- Sanger sequencing
- Immunohistochemistry (IHC)
- Fluorescence in-situ hybridization (FISH)
- Organoid technology
- 2D and 3D cell culturing
- Flow cytometry
- MTT proliferation assays
- Western blotting
- Colony formation, migration and invasion assays
- Molecular profiling of cell lines and tissue samples
- Gene silencing (lentivirus transfection, CRISPR)
We have the capacity to work with formalin-fixed paraffin-embedded tumor tissue, fresh frozen samples, serum, plasma, platelets and cytologies.
BIOMARKER DISCOVERY
Our aim is to elucidate the role genes play in cancer development and use this knowledge to improve patient care through development of novel molecular diagnostic tools. We aim to improve treatment, and therefore survival, through identification of novel theranostic biomarkers that can be rapidly incorporated into clinical practice.
IN-VITRO TESTING
- In vitro drug profiling
- Service & ideas providers for development of new anti-cancer drugs
- “In-vitro” and “In-vivo” analysis
- Development of cell lines resistant to drugs on the market
- We apply cutting-edge technology for the study of the in vitro effect of drugs and vaccines and the search of biomarkers associated to drug sensitivity
- Molecular characterization of different cellular models
- We currently count with a biobank of more than 300 cell lines associated with different clinically relevant molecular alterations, including 30 primary culture cell lines from patient derived from ascites and pleural effusions